Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.

Bombesin (BBN), an analog of human gastrin-releasing peptide (GRP), binds to the GRP receptor (GRPR) with high affinity and specificity. Overexpression of GRPR has been discovered in mostly androgen-independent human prostate tissues and, thus, provides a potential target for prostate cancer diagnosis and therapy. We have previously demonstrated the feasibility of the positron emission tomography (PET) imaging using 64Cu-1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid (DOTA)-[Lys3]BBN to detect GRPR-positive prostate cancer. In this study, we compared the receptor affinity, metabolic stability, tumor-targeting efficacy, and pharmacokinetics of a truncated BBN analog 64Cu-DOTA-Aca-BBN(7-14) with 64Cu-DOTA-[Lys3]BBN. Binding of each DOTA conjugate to GRPR on PC-3 and 22Rv1 prostate cancer cells was evaluated with competitive binding assay using 125I-[Tyr4]BBN as radioligand. In vivo pharmacokinetics was determined on male nude mice subcutaneously implanted with PC-3 cells. Dynamic microPET imaging was performed to evaluate the systemic distribution of the tracers. Metabolic stability of the tracers in blood, urine, tumor, liver and kidney was studied using high-performance liquid chromatography. The results showed that 125I-[Tyr4]BBN has a K(d) of 14.8+/-0.4 nM against PC-3 cells, and the receptor concentration on PC-3 cell surface is approximately 2.7+/-0.1 x 10(6) receptors per cell. The 50% inhibitory concentration value for DOTA-Aca-BBN(7-14) is 18.4 +/- 0.2 nM, and that for DOTA-[Lys3]BBN is 2.2 +/- 0.5 nM. DOTA-[Lys3]BBN shows a better tumor contrast and absolute tumor activity accumulation compared to DOTA-Aca-BBN(7-14). Studies on metabolic stability for both tracers on organ homogenates showed that 64Cu-DOTA-[Lys3]BBN is relatively stable. This study demonstrated that both tracers are suitable for targeted PET imaging to detect the expression of GRPR in prostate cancer, while 64Cu-DOTA-[Lys3]BBN may have a better potential for clinical translation.

[1]  U. Haberkorn,et al.  (68)Ga-labeled peptides in tumor imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  G. de Vincentis,et al.  Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. , 2002, Cancer biotherapy & radiopharmaceuticals.

[3]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[4]  R. Benya,et al.  Increased frequency of gastrin‐releasing peptide receptor gene mutations during colon‐adenocarcinoma progression , 2003, Molecular carcinogenesis.

[5]  A. Schonbrunn,et al.  Bombesin receptors in a human duodenal tumor cell line: binding properties and function. , 1994, Cancer research.

[6]  A. Schally,et al.  Bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H‐69 small cell lung carcinoma , 1998, Cancer.

[7]  G. Jenster,et al.  The role of the androgen receptor in the development and progression of prostate cancer. , 1999, Seminars in oncology.

[8]  B. Roos,et al.  Gastrin-releasing peptide gene expression in developing, hyperplastic, and neoplastic human thyroid C-cells. , 1988, Endocrinology.

[9]  Daniel C. Hill,et al.  Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) Complexes , 2000 .

[10]  The natural history of prostate cancer , 2003 .

[11]  E. Cartwright,et al.  Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours , 2004, Journal of Clinical Pathology.

[12]  S. Cherry,et al.  Simultaneous PET and MR imaging , 1997, Physics in medicine and biology.

[13]  G. Slegers,et al.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.

[14]  E. Rodríguez-Martín,et al.  Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs , 1999, Journal of Cancer Research and Clinical Oncology.

[15]  D. Chung,et al.  Bombesin stimulates growth of human gastrinoma. , 1992, Surgery.

[16]  M. Ciomei,et al.  Bombesin stimulates growth of human prostatic cancer cells in vitro , 1990, Cancer.

[17]  C. Townsend,et al.  Roles of gastrointestinal hormones in pancreatic cancer. , 2000, Journal of hepato-biliary-pancreatic surgery.

[18]  T. H. van der Kwast,et al.  Androgen‐independent growth is induced by neuropeptides in human prostate cancer cell lines , 2000, The Prostate.

[19]  Weijun Niu,et al.  Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. , 2004, Journal of medicinal chemistry.

[20]  Jiehua Zhou,et al.  Targeting gastrin-releasing peptide receptors for cancer treatment , 2004, Anti-cancer drugs.

[21]  P. Cutler,et al.  Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  A. Schally,et al.  Chemotherapy targeted to cancers through tumoral hormone receptors , 2004, Trends in Endocrinology & Metabolism.

[23]  A. Jemal,et al.  Contemporary Lung Cancer Trends among U.S. Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[24]  Heiko Schöder,et al.  Positron emission tomography for prostate, bladder, and renal cancer. , 2004, Seminars in nuclear medicine.

[25]  M. Wuest,et al.  Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. , 2002, Journal of medicinal chemistry.

[26]  Takako Yamaguchi,et al.  Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  M. Coel,et al.  Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. , 2005, The Journal of urology.

[28]  J. Barrio,et al.  Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  T. Hoffman,et al.  Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. , 2003, Nuclear medicine and biology.

[30]  G. Slegers,et al.  Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? , 2001, Nuclear medicine communications.

[31]  A. Schally,et al.  Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers , 2000, The Prostate.

[32]  G. de Vincentis,et al.  Gastrin-releasing peptide (GRP) analogues for cancer imaging. , 2004, Cancer biotherapy & radiopharmaceuticals.

[33]  F Dumont,et al.  Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Pomper,et al.  PET imaging of GRP receptor expression in prostate cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  S. Achilefu,et al.  Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator , 2004, Clinical Cancer Research.

[36]  A. Safavy,et al.  In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. , 2004, Cancer biotherapy & radiopharmaceuticals.

[37]  L. Bégin,et al.  Neuroendocrine differentiation and the bombesin/gastrin‐releasing peptide family of neuropeptides in the progression of human prostate cancer , 1998, The Prostate. Supplement.

[38]  L. Kvols,et al.  Peptide Receptor Radionuclide Therapy , 2004, Annals of the New York Academy of Sciences.

[39]  Magnus Dahlbom,et al.  Radiation dose estimates in humans for (11)C-acetate whole-body PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  U. Haberkorn,et al.  GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Joonyoung Kim,et al.  MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.

[42]  Ryan Park,et al.  microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.